5th Global Conference on Myositis

March 13-16, Pittsburgh, USA - hybrid

A unique opportunity to meet and discuss topics on myositis research from different perspectives. Strong attention has been paid to stimulating the active participation of young physicians and scientists.

Registration open

****************************************************************

4th International Scientific Congress on SMA

Ghent, Belgium, 14-16 March 2024

The goal of the scientific congress is to bring together an international and multi-disciplinary group of scientists and health-care professionals.

Info and registration

**********************************************

Myology 2024

Paris, 22-25 April 2024

This conference offers a comprehensive overview of the latest breakthroughs in muscle science, with a particular focus on disease-modifying therapies and medical advancements for neuromuscular diseases .

Registration open

**************************************************************

Rare Disease Day 2024

2. März 2024, Bern

Neues über kosek, Schweizer Register seltene Krankheiten, nationales Konzept seltene Krankheiten, Zentren Seltene Krankheiten.

Programm und Anmeldung​​​​​​​

**********************************************************

ENMC workshops

The call for regular workshop applications is open.

The call for themed workshop application is open and focuses on two topics: 1. Challenges of complex drugs and therapies in neuromuscular disorders; 2. Artificial intelligence (AI) and/or data sharing in neuromuscular disorders 
Deadline: 1 March 2024

How to submit a workshop application

***********************************

14th International Myotonic Dystrophy Consortium Meeting

Nijmegen, The Netherlands, 9-13 April 2024

A great opportunity to learn, share, and network with all those currently active in the field of myotonic dystrophy: scientists, clinicians, patients, patient representatives, and professionals from the pharmaceutical industry. 

Registration open

***********************************************

New papers

___________________________________

A model of human neural networks reveals NPTX2 pathology in ALS and FTLD.

Hruska-Plochan M, Wiersma VI, Betz KM, Mallona I, Ronchi S, Maniecka Z, Hock EM, Tantardini E, Laferriere F, Sahadevan S, Hoop V, Delvendahl I, Pérez-Berlanga M, Gatta B, Panatta M, van der Bourg A,...

14 Februar 2024

Direct reprogramming of non-limb fibroblasts to cells with properties of limb progenitors.

Atsuta Y, Lee C, Rodrigues AR, Colle C, Tomizawa RR, Lujan EG, Tschopp P, Galan L, Zhu M, Gorham JM, Vannier JP, Seidman CE, Seidman JG, Ros MA, Pourquié O, Tabin CJ.
Dev Cell. 2024 Feb...

05 Februar 2024

Autoreactive T cells target peripheral nerves in Guillain-Barré syndrome.

Súkeníková L, Mallone A, Schreiner B, Ripellino P, Nilsson J, Stoffel M, Ulbrich SE, Sallusto F, Latorre D.
Nature. 2024 Jan 17. doi: 10.1038/s41586-023-06916-6.

17 Januar 2024

Native collagen VI delays muscle stem cell early differentiation.

Metti S, Ros FD, Toniato G, Cescon M, Bonaldo P.
J Cell Sci. 2024 Jan 15:jcs.261419.

15 Januar 2024

The ER stress sensor IRE1 interacts with STIM1 to promote store-operated calcium entry, T cell activation, and muscular differentiation.

Carreras-Sureda A, Zhang X, Laubry L, Brunetti J, Koenig S, Wang X, Castelbou C, Hetz C, Liu Y, Frieden M, Demaurex N.
Cell Rep. 2023 Dec 26;42(12):113540.

26 Dezember 2023

Respiratory function in a large cohort of treatment-naïve adult spinal muscular atrophy patients: a cross-sectional study.

Vicino A, Bello L, Bonanno S, Govoni A, Cerri F, Ferraro M, Capece G, Gadaleta G, Meneri M, Vacchiano V, Ricci G, D'Errico E, Tramacere I, Banfi P, Bortolani S, Zanin R, Maioli MA, Silvestrini M,...

22 Dezember 2023

Functional characterization of RYR1 variants identified in malignant hyperthermia susceptible individuals.

Noda Y, Miyoshi H, Benucci S, Gonzalez A, Bandschapp O, Girard T, Treves S, Zorzato F.
Neuromuscul Disord. 2023 Dec;33(12):951-963

14 Dezember 2023

Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis.

Dohrn MF, Beijer D, Lone MA, Bayraktar E, Oflazer P, Orbach R, Donkervoort S, Foley AR, Rose A, Lyons M, Louie RJ, Gable K, Dunn T, Chen S, Danzi MC, Synofzik M, Bönnemann CG, Nazlı Başak A,...

01 Dezember 2023

Recurrent de novo SPTLC2 variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis.

Syeda SB, Lone MA, Mohassel P, Donkervoort S, Munot P, França MC Jr, Galarza-Brito JE, Eckenweiler M, Asamoah A, Gable K, Majumdar A, Schumann A, Gupta SD, Lakhotia A, Shieh PB, Foley AR, Jackson KE,...

01 Dezember 2023

Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders.

Gomez Limia C, Baird M, Schwartz M, Saxena S, Meyer K, Wein N.
J Pers Med. 2022 Nov 30;12(12):1979.

16 November 2023